Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatic artery embolization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Hepatic artery embolization. Displaying page 1 of 1.
    EudraCT Number: 2017-004859-22 Sponsor Protocol Number: UF9888 Start Date*: 2018-04-12
    Sponsor Name:University Hospital of Monptellier
    Full Title: Treatment of hepatocellular carcinoma on child cirrhosis A/B7 by intra-arterial injection of a Lipiodol and Idarubicin emulsion : a multicentric single-arm phase II study
    Medical condition: The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000270-28 Sponsor Protocol Number: NL75171.058.20 Start Date*: 2022-06-30
    Sponsor Name:Leiden University Medical Center
    Full Title: Selective Indocyanine Green Injection of a Segmental Hepatic Artery Followed by Near-Infrared Fluorescence Guided Anatomical Liver Resection: A Feasibility Study
    Medical condition: Hepatocellular carcinoma, hepatic adenoma, intrahepatic cholangiocarcinoma, colorectal liver metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002041-36 Sponsor Protocol Number: POLARIS2009-001 Start Date*: 2011-11-15
    Sponsor Name:Polaris Group
    Full Title: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Fai...
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-000798-31 Sponsor Protocol Number: NEMA-0027-018 Start Date*: 2007-03-02
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004506-10 Sponsor Protocol Number: LOLATrial Start Date*: 2020-03-13
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
    Medical condition: gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 10:58:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA